Are Peptides Legal in Australia? Complete TGA Guide (2026)
11 min read
Scientific & Legal Research Guide
Are Peptides Legal in Australia?
Complete TGA Guide (2026)
Last updated: May 2026 · Reviewed by the Elite Peps Australia Research Division
Author: Elite Peps Australia Research Division · About the Author
✓ Executive Summary
- Most therapeutic peptides are classified as Schedule 4 (prescription-only) under the TGA's Poisons Standard, including BPC-157, TB-500, CJC-1295, and Ipamorelin.
- Melanotan II was reclassified to Schedule 9 (prohibited substance) in February 2026. Possession now carries criminal penalties.
- Human Growth Hormone (HGH) is Schedule 8 (controlled drug) — the strictest classification before outright prohibition.
- Several peptides — including GHK-Cu, Semax, Selank, MOTS-C, and Retatrutide — are not individually named in the Poisons Standard and exist in a regulatory grey area.
- Semaglutide (Wegovy) is expected to receive PBS listing in mid-2026, significantly improving access for eligible Australians.
- Penalties for unauthorised possession or supply vary by state — from $2,200 in NSW up to $80,650 in Queensland.
- All products sold by Elite Peps Australia are strictly for research purposes only and are not intended for human consumption.
☰ Table of Contents
- Introduction: Why Peptide Legality Is So Confusing
- How Australia Regulates Peptides: The TGA Framework
- Complete Peptide Scheduling Guide
- Schedule Comparison: S4 vs S8 vs S9 vs Unscheduled
- State-by-State Penalty Breakdown
- Melanotan II: The Schedule 9 Reclassification
- BPC-157: Australia's World-First Scheduling Decision
- GLP-1 Peptides: Semaglutide, Tirzepatide & the PBS
- How to Access Peptides Legally in Australia
- TGA Enforcement Timeline
- Upcoming Regulatory Changes
- Frequently Asked Questions
- References
Introduction: Why Peptide Legality in Australia Is So Confusing
If you have ever searched "are peptides legal in Australia," you already know that getting a straight answer is surprisingly difficult. Peptide legality in Australia is not a simple yes-or-no question — it depends entirely on which peptide, what schedule it falls under, what state you are in, and what you intend to use it for.
Australia has one of the most complex peptide regulatory frameworks in the world. The Therapeutic Goods Administration (TGA) classifies substances through the Poisons Standard (SUSMP), updated multiple times per year. State and territory governments then enforce these classifications through their own legislation — with different penalties in each jurisdiction.
"The Australian regulatory landscape for peptides is among the most dynamic in the world. Unlike the US FDA or EU EMA, the TGA has demonstrated a willingness to schedule individual compounds rapidly — as seen with BPC-157 in 2024 and Melanotan II in 2026. Researchers and suppliers must monitor the Poisons Standard on a quarterly basis." — Elite Peps Australia Research Division
How Australia Regulates Peptides: The TGA Framework
The TGA operates under the Therapeutic Goods Act 1989 (Cth). They regulate compounds via two main pillars:
A national classification system categorising substances based on risk. The current edition is the Therapeutic Goods (Poisons Standard — February 2026) Instrument 2026.
A database of goods approved for supply. Peptides NOT on the ARTG are classified as unapproved therapeutic goods if marketed for human use, regardless of scheduling status.
Complete Peptide Scheduling Guide: Every Major Compound
The following tables represent the most comprehensive peptide scheduling reference available for Australia, mapped to the February 2026 Poisons Standard.
Schedule 4 — Prescription Only Medicines
| Compound | Category | Year Scheduled | Regulatory Note |
|---|---|---|---|
| BPC-157 | Recovery | June 2024 | Australia was the first country to specifically schedule BPC-157 |
| TB-500 (Thymosin Beta-4) | Recovery | 2015 | Classified as a PIED under Appendix D Item 5 |
| CJC-1295 | GH Axis | 2014 | Scheduled as a class with all GH secretagogues |
| Ipamorelin | GH Axis | 2014 | Named individually in addition to class scheduling |
| Sermorelin | GH Axis | 2014 | GH releasing hormone analogue |
| GHRP-6 | GH Axis | 2014 | GH releasing peptide |
| Hexarelin | GH Axis | 2014 | GH releasing peptide |
| AOD-9604 | Metabolic | 2014 | Modified GH fragment (177-191) |
| HGH Fragment | GH Axis | 2014 | Growth hormone fragment |
| MK-677 (Ibutamoren) | GH Axis | 2020 | Individually named to clarify scheduling of online sales |
| PT-141 (Bremelanotide) | Sexual Health | 2015 | Melanocortin receptor agonist |
| Semaglutide | GLP-1 | S4 + ARTG | TGA-approved as Ozempic and Wegovy. PBS listing expected mid-2026 |
| Tirzepatide | GLP-1 | S4 + ARTG | TGA-approved as Mounjaro. PBS submission under review |
Schedule 8 — Controlled Drug
| Compound | Category | Notes |
|---|---|---|
| Human Growth Hormone (Somatropin) | GH Axis | Strictest scheduling before prohibition. Requires S8 prescribing authority |
Schedule 9 — Prohibited Substance
| Compound | Category | Date Reclassified | Notes |
|---|---|---|---|
| Melanotan II | Tanning | February 2026 | Moved from S4 to S9. 89 adverse event reports including two melanoma cases. Criminal penalties apply. |
Not Individually Scheduled (Regulatory Grey Area)
| Compound | Category | Status |
|---|---|---|
| GHK-Cu | Anti-Aging | Not scheduled. Regulated if therapeutic claims are made |
| Epithalon | Longevity | Not scheduled. Regulated if therapeutic claims are made |
| KPV | Anti-Inflammatory | Not scheduled. Regulated if therapeutic claims are made |
| Semax | Cognitive | Not scheduled. Regulated if therapeutic claims are made |
| Selank | Cognitive | Not scheduled. Regulated if therapeutic claims are made |
| Thymosin Alpha-1 | Immune | Not individually scheduled. Subject to unapproved TG regulation |
| MOTS-C | Longevity | Not scheduled. Regulated if therapeutic claims are made |
| Tesamorelin | GH Axis | Not individually named but may fall under GH class scheduling |
| Retatrutide | GLP-1 | Not scheduled. Currently in Phase 3 clinical trials (TRIUMPH program) |
| SS-31 (Elamipretide) | Longevity | Not scheduled. Regulated if therapeutic claims are made |
| NAD+ | Longevity | Not scheduled in injectable form. Available as supplement in oral form |
Schedule Comparison: S4 vs S8 vs S9 vs Unscheduled
| Criteria | Schedule 4 | Schedule 8 | Schedule 9 | Unscheduled |
|---|---|---|---|---|
| Access | Prescription required | Prescription + S8 authority | Approved research only | Context-dependent |
| Penalty Type | Regulatory fine | Regulatory fine + criminal | Criminal charges | Varies |
| Max Penalty (QLD) | $32,260 | Higher penalties apply | Criminal prosecution | N/A if no claims made |
| Research Use | Permitted with oversight | Highly restricted | Approved trials only | Generally permitted |
| Examples | BPC-157, TB-500, Semaglutide | HGH (Somatropin) | Melanotan II | GHK-Cu, Retatrutide, NAD+ |
State-by-State Penalty Breakdown
Enforcement occurs through state and territory legislation. Penalties vary severely depending on your location in Australia.
| State/Territory | Legislation | Max Penalty (Possession) | Max Penalty (Supply) |
|---|---|---|---|
| New South Wales | Poisons and Therapeutic Goods Act 1966 | $2,200 / 6mo imprisonment | $1,650 / 6mo imprisonment |
| Victoria | Drugs, Poisons and Controlled Substances Act 1981 | $19,759 fine | $19,759 fine |
| Queensland | Medicines and Poisons Act 2019 | $32,260 fine | $80,650 fine |
| Western Australia | Poisons Act 1964 | $30,000 / 2yrs imprisonment | $30,000+ / imprisonment |
| South Australia | Controlled Substances Act 1984 | Varies by substance | Varies by substance |
| Tasmania | Poisons Act 1971 | $9,750 / 2yrs imprisonment | $3,900 fine |
| ACT | Medicines, Poisons and Therapeutic Goods Act 2008 | Varies — prescription required | Varies — authorisation required |
| Northern Territory | Medicines, Poisons and Therapeutic Goods Act 2012 | Varies — prescription required | Varies — authorisation required |
"Queensland's penalty structure is an outlier in the Australian context. The $80,650 maximum supply penalty under the Medicines and Poisons Act 2019 is nearly five times the equivalent NSW penalty. Researchers and suppliers operating nationally must calibrate their compliance posture to the most restrictive jurisdiction." — Elite Peps Australia Research Division
Melanotan II: The Schedule 9 Reclassification (February 2026)
The most significant peptide regulatory change in recent Australian history occurred in February 2026, when the TGA reclassified Melanotan II from Schedule 4 to Schedule 9 — the same category as MDMA and heroin.
- 89 adverse event reports submitted to the TGA between 2022 and 2025
- Two melanoma diagnoses within 18 months of Melanotan II use
- Concerns about non-selective melanocortin receptor activation
- Widespread social media promotion and non-medical use
Under Schedule 9, Melanotan II possession carries criminal charges in all Australian states and territories — not just regulatory fines.
BPC-157: Australia's World-First Scheduling Decision
In June 2024, Australia became the first country in the world to specifically add BPC-157 to its national scheduling system as Schedule 4 (Prescription Only). The scheduling was driven by rapidly increasing importation volumes, widespread online marketing with therapeutic claims, lack of completed human clinical trials, and growing use outside medical supervision.
BPC-157 remains available for legitimate research purposes. Elite Peps Australia offers research-grade BPC-157 independently tested in Australian laboratories to 99%+ purity. See our complete BPC-157 research guide.
GLP-1 Peptides: Semaglutide, Tirzepatide & the PBS
Several GLP-1 compounds are TGA-approved and listed on the ARTG: Semaglutide (Ozempic/Wegovy), Tirzepatide (Mounjaro), and Liraglutide (Saxenda). The PBAC recommended Wegovy (semaglutide 2.4mg) for PBS listing in November 2025, expected in mid-2026. Research-only GLP-1 compounds like Retatrutide are not TGA-approved and available only as research compounds.
How to Access Peptides Legally in Australia
Any AHPRA-registered medical practitioner can prescribe Schedule 4 peptides, fulfilled via a TGA-licensed compounding pharmacy.
Legally equivalent to in-person consultations for S4 medicines across all Australian states and territories.
Allows prescribing of unapproved therapeutic goods for individual patients. SAS Category B requires individual TGA approval before supply.
Via the CTN/CTA schemes with ethics committee approval and registration on the ANZCTR.
All Elite Peps Australia products are sold exclusively for research use with independent Australian lab verification of purity.
TGA Enforcement Timeline
What the Future Holds: Upcoming Regulatory Changes
- More compounds may be scheduled — Compounds with high recreational or cosmetic use patterns are most at risk.
- PBS GLP-1 expansion — Wegovy PBS listing in mid-2026 will dramatically increase Australian access to semaglutide.
- Increased border enforcement — The 847 seizures in Q1 2026 suggest continued escalation of import enforcement.
- Compounding pharmacy audits — Targeted audits focusing on sterility, ingredient sourcing, and prescribing practices.
- Advertising enforcement — The TGA continues to prosecute suppliers making therapeutic claims.
🔗 Related Research Guides
Frequently Asked Questions
Are research peptides legal to buy in Australia?
Research peptides sold strictly for laboratory and scientific purposes, with no therapeutic claims, operate under different regulatory considerations than therapeutic goods. However, the regulatory environment is complex and evolving. Scheduled compounds (S4, S8, S9) have specific legal requirements regardless of stated purpose.
Can I import peptides from overseas into Australia?
Importing scheduled peptides without TGA authorisation is a regulatory offence. The TGA seized 847 peptide shipments in Q1 2026 alone. Section 19 import permits are recommended for all peptide imports.
Is BPC-157 legal in Australia?
BPC-157 is Schedule 4 (Prescription Only) as of June 2024. It can be legally prescribed by a registered medical practitioner and dispensed through a compounding pharmacy. Possession without a prescription may constitute a regulatory breach with penalties varying by state.
What happened with Melanotan II?
Melanotan II was reclassified from Schedule 4 to Schedule 9 in February 2026, following 89 adverse event reports including two melanoma diagnoses. Possession now carries criminal penalties across all Australian jurisdictions.
Will the TGA schedule more peptides?
The TGA regularly reviews substances based on adverse event reports, misuse patterns, and public health data. The trend over recent years has been toward increased regulation. Compounds with high non-medical use patterns are most likely to be scheduled next.
Can my doctor prescribe peptides?
Yes. Any AHPRA-registered medical practitioner can prescribe Schedule 4 peptides, including via telehealth. Prescriptions are typically fulfilled through TGA-licensed compounding pharmacies.
When will semaglutide be available on the PBS?
The PBAC recommended Wegovy (semaglutide 2.4mg) for PBS listing in November 2025. The listing is expected in mid-2026 pending pricing negotiations with Novo Nordisk.
What is the difference between Schedule 4 and Schedule 9?
Schedule 4 substances are Prescription Only Medicines — legal with a valid prescription. Schedule 9 substances are Prohibited — possession carries criminal penalties, not just regulatory fines.
References
- Therapeutic Goods (Poisons Standard — February 2026) Instrument 2026. Federal Register of Legislation. Canberra: Australian Government.
- Therapeutic Goods Act 1989 (Cth). Federal Register of Legislation.
- Secretary, Department of Health v Peptide Clinics Australia Pty Ltd [2019] FCA 1107. Federal Court of Australia.
- Therapeutic Goods Administration. (2026). The Poisons Standard and Scheduling of Medicines and Chemicals. tga.gov.au.
- Mills Oakley. (2026). Peptides in Australia — Recent TGA Enforcement Action. millsoakley.com.au.
- Poisons and Therapeutic Goods Act 1966 (NSW). NSW Government.
- Drugs, Poisons and Controlled Substances Act 1981 (VIC). Victorian Government.
- Medicines and Poisons Act 2019 (QLD). Queensland Government.
- Poisons Act 1964 (WA). Western Australian Government.
- Poisons Act 1971 (TAS). Tasmanian Government.
- Pharmaceutical Benefits Advisory Committee. (2025). PBAC Positive Recommendation: Semaglutide (Wegovy). Australian Government Department of Health.
This article is for educational and informational purposes only. It does not constitute legal advice. Australian peptide regulations are subject to change. Always consult the TGA website for the most current scheduling information, and seek qualified legal advice. All products sold by Elite Peps Australia are strictly for laboratory and scientific research purposes only. They are not intended for human consumption, therapeutic use, or self-administration.
Ready to Order?
Browse our full range of 99%+ purity research peptides. Australian lab tested. Free express shipping over $100.
Shop All Peptides